Practice Areas - Equity Capital Markets Law Firms and Lawyers
| Deal Date: | 14-07-2020 | Practice Area: | Equity Capital Markets |
| Deal Title: | Revolution Medicines Common Stock Follow-On Offering | Industry: | Pharmaceuticals & Biotechnology |
| Description: |
Davis Polk advised the underwriters in connection with a public offering of 6,900,000 shares of common stock of Revolution Medicines, Inc. at USD26.00 per share (which included the exercise in full by the underwriters of their option to purchase up to 900,000 additional shares), for total gross proceeds of USD179.4 million. The common stock was listed on the Nasdaq Global Select Market under the symbol RVMD.
Based in Redwood City, California, Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, high-value frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways.
|
||
| Financial Center: | Silicon Valley | Value: | 100.01-500.00 |
| Advised Party: | Underwriter | Law Firm | Davis Polk |
| Issuer Jurisdiction - | United States | Listing Jurisdiction - | United States |
| Classification: |
Secondary Offerings and Placings NASDAQ: |
Lawyer | Alan F Denenberg |
